BR112015010823A2 - composto de 2-piridona - Google Patents

composto de 2-piridona

Info

Publication number
BR112015010823A2
BR112015010823A2 BR112015010823A BR112015010823A BR112015010823A2 BR 112015010823 A2 BR112015010823 A2 BR 112015010823A2 BR 112015010823 A BR112015010823 A BR 112015010823A BR 112015010823 A BR112015010823 A BR 112015010823A BR 112015010823 A2 BR112015010823 A2 BR 112015010823A2
Authority
BR
Brazil
Prior art keywords
compound
pyridone compound
pyridone
tautomer
solvate
Prior art date
Application number
BR112015010823A
Other languages
English (en)
Portuguese (pt)
Inventor
Asanuma Hajime
Ota Hirofumi
Fusegi Keiko
Mizutani Marie
Bohno Masahiro
Sato Nagaaki
Ishiyama Seishi
Sasako Shigetada
Itoh Shin
Kuroda Shoichi
Monma Souichi
Kawaguchi Takanori
Okada Takumi
Chonan Tomomichi
Imai Yudai
Original Assignee
Nissan Chemical Ind Ltd
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Ind Ltd
Publication of BR112015010823A2 publication Critical patent/BR112015010823A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BR112015010823A 2012-11-13 2013-11-12 composto de 2-piridona BR112015010823A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 2-ピリドン化合物

Publications (1)

Publication Number Publication Date
BR112015010823A2 true BR112015010823A2 (pt) 2017-07-11

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010823A BR112015010823A2 (pt) 2012-11-13 2013-11-12 composto de 2-piridona

Country Status (25)

Country Link
US (1) US9695148B2 (enExample)
EP (1) EP2921489B1 (enExample)
JP (1) JP5963025B2 (enExample)
KR (1) KR102160841B1 (enExample)
CN (1) CN104768944B (enExample)
AU (1) AU2013345930B2 (enExample)
BR (1) BR112015010823A2 (enExample)
CA (1) CA2891406C (enExample)
DK (1) DK2921489T3 (enExample)
ES (1) ES2641469T3 (enExample)
HU (1) HUE034557T2 (enExample)
IL (1) IL238701B (enExample)
IN (1) IN2015DN03869A (enExample)
MX (1) MX361479B (enExample)
MY (1) MY173812A (enExample)
NO (1) NO2921489T3 (enExample)
NZ (1) NZ707832A (enExample)
PH (1) PH12015501056A1 (enExample)
PL (1) PL2921489T3 (enExample)
PT (1) PT2921489T (enExample)
RU (1) RU2662157C2 (enExample)
SG (1) SG11201503716RA (enExample)
TW (1) TWI591064B (enExample)
WO (1) WO2014077235A1 (enExample)
ZA (1) ZA201503323B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 2−ピリドン化合物を含有する医薬
CN106573909A (zh) * 2014-05-13 2017-04-19 日产化学工业株式会社 2‑吡啶酮化合物的制造方法
DK3804716T3 (da) 2018-05-31 2025-03-03 Hua Medicine Shanghai Ltd Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
HRP20010688B1 (en) 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
WO2008103185A2 (en) 2006-06-08 2008-08-28 Eli Lilly And Company Substituted carboxamides as group i metabotropic receptor antagonists
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
EA018709B1 (ru) * 2007-07-17 2013-10-30 Бристол-Маерс Сквибб Компани Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
JP5750050B2 (ja) * 2009-12-04 2015-07-15 大正製薬株式会社 2−ピリドン化合物
JP2013010750A (ja) 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd 2−ピリドン化合物を含有する医薬

Also Published As

Publication number Publication date
MX2015005884A (es) 2015-12-09
EP2921489B1 (en) 2017-09-06
CN104768944B (zh) 2017-03-29
TW201434826A (zh) 2014-09-16
WO2014077235A1 (ja) 2014-05-22
SG11201503716RA (en) 2015-06-29
CA2891406A1 (en) 2014-05-22
MY173812A (en) 2020-02-24
PL2921489T3 (pl) 2018-01-31
JPWO2014077235A1 (ja) 2017-01-05
AU2013345930A1 (en) 2015-06-04
RU2015122717A (ru) 2017-01-10
TWI591064B (zh) 2017-07-11
MX361479B (es) 2018-12-06
EP2921489A1 (en) 2015-09-23
NZ707832A (en) 2019-03-29
US9695148B2 (en) 2017-07-04
RU2662157C2 (ru) 2018-07-24
AU2013345930B2 (en) 2017-08-24
ZA201503323B (en) 2016-08-31
PT2921489T (pt) 2017-12-01
KR102160841B1 (ko) 2020-09-28
US20160289208A1 (en) 2016-10-06
DK2921489T3 (en) 2017-10-16
EP2921489A4 (en) 2016-04-06
KR20150082301A (ko) 2015-07-15
IL238701B (en) 2018-10-31
ES2641469T3 (es) 2017-11-10
IL238701A0 (en) 2015-06-30
HK1207856A1 (en) 2016-02-12
PH12015501056B1 (en) 2015-07-27
IN2015DN03869A (enExample) 2015-10-02
CN104768944A (zh) 2015-07-08
NO2921489T3 (enExample) 2018-02-03
CA2891406C (en) 2021-03-16
JP5963025B2 (ja) 2016-08-03
PH12015501056A1 (en) 2015-07-27
HUE034557T2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
IN2014MN02106A (enExample)
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
BR112014026266A2 (pt) derivado de quinazolidinadiona
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112012031340A2 (pt) derivados de cianoquinolina
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
BR112015029348A2 (pt) inibidores da bace
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112014026305A2 (pt) derivado de quinazolidinadiona
MX390763B (es) Compuestos de tetraciclina
PH12015501386A1 (en) Tricyclic compounds
MX2016014939A (es) Derivados de carboxamida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: NISSAN CHEMICAL INDUSTRIES, LTD. (JP)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements